Valuation: Beijing Strong Biotechnologies,Inc.

Capitalization	8.33B 1.2B 1.02B 943M 882M 1.64B 110B 1.74B 10.78B 4.28B 51.91B 4.49B 4.4B 189B	P/E ratio 2025 *	15.4x	P/E ratio 2026 *	13.3x
Enterprise value	8.33B 1.2B 1.02B 943M 882M 1.64B 110B 1.74B 10.78B 4.28B 51.91B 4.49B 4.4B 189B	EV / Sales 2025 *	4.98x	EV / Sales 2026 *	4.38x
Free-Float	38.14%	Yield 2025 *	2.81%	Yield 2026 *	3.3%

More valuation ratios * Estimated data

Chart: Beijing Strong Biotechnologies,Inc.

Timeframe

Style

Dynamic Chart

Latest news: Beijing Strong Biotechnologies,Inc.

12-18	Beijing Strong Biotechnologies Obtains Three Patent Certificates	MT
12-08	China National Pharmaceutical Investment Co., Ltd. signed a Share Transfer Agreement to acquire an additional 5% stake in Beijing Strong Biotechnologies,Inc. from Zou Zuojun, Liu Xi, and Sun Xiaolin for approximately CNY 400 million.	CI
11-19	Beijing Strong Biotechnologies Secures Beijing Regulatory Approval for Assay Kit	MT
11-17	Beijing Strong Biotechnologies,Inc. Approves Cash Dividend on A Shares for Third Quarter 2025, Payable on 27 November 2025	CI
29/10/25	Beijing Strong Biotechnologies,Inc. Proposes Profit Distribution Plan for Third Quarter 2025	CI
28/10/25	Beijing Strong Biotechnologies,Inc. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
21/10/25	Beijing Strong Biotechnologies Gets Regulatory Nod for Heart Failure Hormone Detection Kit	MT
16/09/25	Beijing Strong Biotechnologies Gets Beijing Approval for Gastrin 17 Assay Kit	MT
03/09/25	Beijing Strong Biotechnologies Gets Approval for Inflammation Marker Detection Kit	MT
03/09/25	Beijing Strong Biotechnologies Gets China Approval for Gastrin-17 Detection Kit	MT
27/08/25	Beijing Strong Biotechnologies,Inc. Proposes Interim Dividend Plan on A Share for 2025, Payable on 05 September 2025	CI
26/08/25	Beijing Strong Biotechnologies,Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
17/06/25	Beijing Strong Biotechnologies Gets Medical Device Registration for Assay Kit	MT

More news

News in other languages: Beijing Strong Biotechnologies,Inc.

10/08/22

Forscher entdecken in China neues Henipavirus - 35 Infizierte

More news

Managers and Directors: Beijing Strong Biotechnologies,Inc.

Manager	Title	Age	Since
Hong Jun Liang CEO	Chief Executive Officer	52	21/09/2023
Wei Liu DFI	Director of Finance/CFO	57	31/12/2006
Nan Bao IRC	Investor Relations Contact	46	-

Director	Title	Age	Since
Zuo Jun Zou CHM	Chairman	68	28/03/2001
Xi Liu BRD	Director/Board Member	64	28/03/2001
Ai Ping Luo BRD	Director/Board Member	63	15/03/2011

More insiders

Diagnostic & Testing Substances

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BEIJING STRONG BIOTECHNOLOGIES,INC.	+0.92%	+0.42%	+8.94%	-15.53%	1.2B
GUARDANT HEALTH, INC.	-2.16%	+2.33%	+136.11%	+239.90%	14.78B
BIOMÉRIEUX	-0.86%	-0.86%	-8.07%	+6.12%	14.4B
CARIS LIFE SCIENCES, INC.	-2.15%	-6.65%	-	-	7.05B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-0.99%	-3.68%	-12.15%	+0.11%	6.31B
DIASORIN S.P.A.	-0.33%	-1.80%	-31.13%	-41.52%	4.65B
LANTHEUS HOLDINGS, INC.	+0.49%	+5.07%	-30.85%	+23.67%	4.48B
AUTOBIO DIAGNOSTICS CO., LTD.	+1.28%	+1.14%	-6.35%	-42.99%	3.06B
10X GENOMICS, INC.	-3.49%	+9.06%	+50.20%	-53.30%	2.83B
Average	-0.81%	+0.48%	+13.34%	+14.56%	6.53B
Weighted average by Cap.	-1.19%	+0.35%	+32.30%	+62.80%

See all sector performances

Beijing Strong Biotechnologies Inc. is a China-based company mainly engaged in the research and development, manufacture and sales of in vitro diagnostic reagents. The Companyâs in vitro diagnostic reagents are mainly used in liver, renal, blood fat, glycometabolism and other fields. The Company is also engaged in the manufacture and sales of in vitro diagnostic equipment and the leasing of equipment. The Company operates businesses in domestic and overseas markets.

Employees

1,098

Sector

Medical Equipment, Supplies & Distribution

Calendar

04-22 - Q1 2026 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
23/01/26	14.25 ¥	+0.92%	8,283,186
22/01/26	14.12 ¥	-0.56%	5,681,406
21/01/26	14.20 ¥	+0.35%	7,152,464
20/01/26	14.15 ¥	-1.05%	7,575,700
19/01/26	14.30 ¥	+0.78%	9,922,889

End-of-day quote Shenzhen S.E., January 22, 2026

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

14.25

Average target price

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Shenzhen S.E. Other stock markets 23/01/2026			5-day change	1st Jan Change
14.25 ^CNY	+0.92%		+0.42%	+9.03%

1 day	+0.92%
1 week	+0.42%
Current month	+9.03%
1 month	+7.71%
3 months	+6.82%
6 months	-0.90%
Current year	+9.03%

1 week	14.02	14.35
1 month	13	16.05
Current year	13	16.05
1 year	12.8	17.96
3 years	11.01	24.8
5 years	11.01	25.59
10 years	8.92	25.81

	2025 *	2026 *
Net sales	1.67B 240M 204M 189M 177M 330M 22.06B 350M 2.16B 859M 10.42B 900M 882M 37.89B	1.9B 273M 233M 216M 201M 375M 25.12B 398M 2.46B 978M 11.86B 1.03B 1B 43.14B
Net income	544M 78.2M 66.51M 61.65M 57.61M 107M 7.18B 114M 705M 280M 3.39B 293M 287M 12.34B	634M 90.98M 77.38M 71.72M 67.02M 125M 8.36B 132M 820M 325M 3.95B 341M 334M 14.36B
Net Debt	-	-

Beijing Strong Biotechnologies,Inc. Share Price

Equities

300406

CNE100001Y26